A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

Trial Details

NCT ID
NCT07600476
Phase
PHASE1
Sponsor
Kupando GmbH
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • KUP-101A
Locations (sample)
  • Munich, Bavaria, Germany|48.13743,11.57549
  • Würzburg, Bavaria, Germany|49.79391,9.95121
  • Münster, North Rhine-Westphalia, Germany|51.96236,7.62571

Key Eligibility Criteria

  • Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available
  • ECOG Performance status of 0 to 2
  • Adequate hematological, renal, and hepatic organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →